Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure
Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure
复制标题
DOI：
10.1093/ehjci/jey016
复制
发表时间：
2018-07-01
影响因子：
6.2
通讯作者：
Jacobson, Arnold F.
中科院分区：
文献类型：
--
作者：
Nakajima, Kenichi;Nakata, Tomoaki;Jacobson, Arnold F.
目的 本研究的目的是在新的慢性心力衰竭 (CHF) 患者队列中验证包括 1231-间碘苄基胍 (MIBG) 成像在内的四参数风险模型，该模型先前是为预测心脏死亡率而开发的。 方法和结果 回顾性地从 546 名接受过 1211-MIBG 成像的患者（年龄 66±14 岁）中获得了临床和结果数据。心脏与纵隔比率（HMR）。平均随访时间为 30±20 个月，终点为心源性死亡。使用 Kaplan Meier 生存分析进行心源性死亡和接受者操作特征 (ROC) 分析，将模型预测的死亡率结果与三个或四个风险组的预先指定风险类别中的实际 2 年事件率进行比较。 137 名患者发生心源性死亡，其中 105 名（68%）患者因心力衰竭死亡。该模型将 2 年死亡率风险分为三类低（12%），验证人群中 2 年心脏死亡率分别为 1.1%、7.9% 和 54.7%（P
Aims The aim of this study was to validate a four-parameter risk model including 1231-meta-iodobenzylguanidine (MIBG) imaging, which was previously developed for predicting cardiac mortality, in a new cohort of patients with chronic heart failure (CHF).Methods and results Clinical and outcome data were retrospectively obtained from 546 patients (age 66 14 years) who had undergone 1211-MIBG imaging with a heart-to-mediastinum ratio (HMR). The mean follow-up time was 30 20 months, and the endpoint was cardiac death. The mortality outcome predicted by the model was compared with actual 2-year event rates in pre-specified risk categories of three or four risk groups using Kaplan Meier survival analysis for cardiac death and receiver-operating characteristic (ROC) analysis. Cardiac death occurred in 137 patients, including 105 (68%) patients due to heart-failure death. With a 2-year mortality risk from the model divided into three categories of low- (12%), 2-year cardiac mortality was 1.1%, 7.9%, and 54.7%, respectively in the validation population (P